comparemela.com

Latest Breaking News On - Acasti pharma inc stock exchange - Page 1 : comparemela.com

ACASTI PHARMA INC : Change in Directors or Principal Officers, Other Events (form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 8, 2023, the Company appointed Dr.. | May 11, 2023

United statesUniversity of illinoisUnited kingdomBritish columbiaCarrie dandreaGeorge kottayilR loch macdonaldPierre lemieuxBrian fordPrashant kohliSamresh kumarCommunity health partnersGrace therapeutics incRutgers universityDivision of neurosurgeryProgram management

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

Company successfully submits GTX-104 Pivotal Phase 3 protocol IND amendment to the FDA with expectation for first patient dosed in calendar Q4 2023 Strategic realignment prioritizes GTX-104 and. | May 8, 2023

United statesRobert blumVimal kavuruR loch macdonaldPrashant kohliFletcher spaghtSamresh kumarCarrie dandreaVp program managementExchange commissionCompany nasdaqAcasti pharma incSecurities exchangeLytham partnersNew drug applicationAcasti pharma

Acasti Pharma Inc Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

Acasti also confirms no exposure to Silicon Valley Bank or Silvergate Bank LAVAL, Québec, March 13, 2023 /PRNewswire/ Acasti Pharma Inc. a late-stage, specialty pharma company. | March 13, 2023

United statesRobert blumJan dalviseSilicon valley bankSilvergate bankAcasti pharma incLytham partnersSecurities exchangeRegulation services providerVenture exchangeAcasti pharmaOrphan drug designationSubarachnoid hemorrhagePostherpetic neuralgiaSecurities litigation reform actSecurities act

Acasti Announces Court Dismissal of Stockholder Litigation

LAVAL, Québec, Sept. 30, 2022 Acasti Pharma Inc. , a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases,. | September 30, 2022

New yorkUnited statesKatherine polk faillaRobert blumJan dalviseCompany nasdaqUnited states district courtExchange commissionAcasti pharma incLytham partnersSecurities exchangeGrace therapeutics incRegulation services providerUs securities exchangeGrace therapeuticsExchange act

vimarsana © 2020. All Rights Reserved.